ARYA Sciences Acquisition Corp IV
Status: Live Deal
U=S
IPO Proceeds, $M | $149.50M |
---|---|
IPO Date | Feb 26, 2021 |
CEO | Adam Stone |
Left Lead | Goldman Sachs |
IPO Cash in Trust | 100.0% |
SPAC Tenor | 24 + 12 + 12 |
IPO Sector |
Healthcare
Life sciences and medical technology in North America and Europe |
IPO Geography | Global |
Target Company | Adagio Medical |
Deal Announced | Feb 14, 2024 |
Deal Size, $M | $116.00M |
Deal Sector | Healthcare |
Deal Geography | US/Canada |
SEC Filings | www.sec.gov |
Approval Vote | TBD |
Amendment Vote | Feb 27, 2024 |
ARYD
Price | $11.31 |
---|---|
Last closing price | $11.35 |
H/L, today | $11.35 / $11.39 |
H/L, 52-week | $9.99 / $10.90 |
Volume, today | 1,542 |
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on ARYA Sciences Acquisition Corp IV:
- Structure and cap table
- 7 directors & officers
- 31 filings and events
- 2 underwriters
- 2 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Joseph Edelman | 65 | Chairman |
Adam Stone | 41 | Chief Executive Officer and Director |
Michael Altman | 39 | Chief Financial Officer and Director |
Konstantin Poukalov | 37 | Chief Business Officer |
Todd Wider | 56 | Director |
Leslie Trigg | 50 | Director |
Michael Henderson | 31 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
Goldman Sachs | Joint BR | 6,500,000 | units |
Jefferies | Joint BR | 6,500,000 | |
13,000,000 | units | ||
Up-Front UW fee | 2.00 | % | |
Deferred UW fee | 3.50 | % |
Sign in to view more advisor data.
Filings
Sign in to view 31 filings.